{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:47:08Z","timestamp":1774583228032,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ajp.2017.01.016","type":"journal-article","created":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T12:31:54Z","timestamp":1485520314000},"page":"115-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis"],"prefix":"10.1016","volume":"26","author":[{"given":"Nicholas","family":"Zareifopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Dylja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajp.2017.01.016_bib0005","doi-asserted-by":"crossref","first-page":"d1199","DOI":"10.1136\/bmj.d1199","article-title":"Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis","volume":"342","author":"Baldwin","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ajp.2017.01.016_bib0010","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.euroneuro.2012.07.012","article-title":"Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial","volume":"22","author":"Bidzan","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ajp.2017.01.016_bib0015","unstructured":"Busner, J., Targum, S.D. n.d. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont)."},{"key":"10.1016\/j.ajp.2017.01.016_bib0020","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40263-013-0071-0","article-title":"Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research","volume":"27","author":"Celada","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ajp.2017.01.016_bib0025","first-page":"CD006115","article-title":"Azapirones for generalized anxiety disorder","author":"Chessick","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ajp.2017.01.016_bib0030","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jad.2016.02.042","article-title":"Vortioxetine for major depressive disorder: an indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"196","author":"Citrome","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ajp.2017.01.016_bib0035","first-page":"660","article-title":"Clinical inquiry: how do antidepressants affect sexual function?","volume":"62","author":"Clark","year":"2013","journal-title":"J. Fam. Pract."},{"key":"10.1016\/j.ajp.2017.01.016_bib0040","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2147\/NDT.S103408","article-title":"Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies","volume":"12","author":"Clayton","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"Suppl. 2","key":"10.1016\/j.ajp.2017.01.016_bib0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4088\/JCP.s.7002.05","article-title":"First-line pharmacotherapy approaches for generalized anxiety disorder","volume":"70","author":"Davidson","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2017.01.016_bib0050","article-title":"Efficacy and safety of vilazodone in patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled, flexible-dose trial","author":"Durgam","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2017.01.016_bib0055","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2147\/NDT.S104050","article-title":"The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis","volume":"12","author":"Fu","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.ajp.2017.01.016_bib0060","first-page":"1002","article-title":"Generalised anxiety disorder","volume":"2007","author":"Gale","year":"2007","journal-title":"BMJ Clin. Evid."},{"key":"10.1016\/j.ajp.2017.01.016_bib0065","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/da.22365","article-title":"A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder","volume":"32","author":"Gommoll","year":"2015","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.ajp.2017.01.016_bib0070","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/YIC.0000000000000096","article-title":"Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study","volume":"30","author":"Gommoll","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2017.01.016_bib0075","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00535-012-0726-5","article-title":"Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases","volume":"48","author":"Grover","year":"2013","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.ajp.2017.01.016_bib0080","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.ajp.2017.01.016_bib0085","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/0269881107076996","article-title":"An effect-size analysis of pharmacologic treatments for generalized anxiety disorder","volume":"21","author":"Hidalgo","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ajp.2017.01.016_bib0090","first-page":"CD003592","article-title":"Antidepressants for generalized anxiety disorder","author":"Kapczinski","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ajp.2017.01.016_bib0095","article-title":"Post hoc analyses of anxiety measures in adult patients with generalized anxiety disorder treated with vilazodone","volume":"18","author":"Khan","year":"2016","journal-title":"Prim. Care Companion CNS Disord."},{"key":"10.1016\/j.ajp.2017.01.016_bib0100","doi-asserted-by":"crossref","first-page":"381","DOI":"10.31887\/DCNS.2011.13.4\/elenze","article-title":"A lifespan view of anxiety disorders","volume":"13","author":"Lenze","year":"2011","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.ajp.2017.01.016_bib0105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/ijcp.12328","article-title":"A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder","volume":"68","author":"Mahableshwarkar","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ajp.2017.01.016_bib0110","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hup.2371","article-title":"A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10mg in acute treatment of adults with generalized anxiety disorder","volume":"29","author":"Mahableshwarkar","year":"2014","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.ajp.2017.01.016_bib0115","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/DDDT.S89485","article-title":"Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Maneeton","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"issue":"Suppl. 6","key":"10.1016\/j.ajp.2017.01.016_bib0120","first-page":"26","article-title":"Safety and tolerability of the new antidepressants","volume":"58","author":"Nelson","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2017.01.016_bib0125","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jpsychires.2015.02.017","article-title":"Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis","volume":"64","author":"Pae","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.ajp.2017.01.016_bib0130","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.euroneuro.2012.07.011","article-title":"Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States","volume":"22","author":"Rothschild","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ajp.2017.01.016_bib0135","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4306\/pi.2015.12.2.155","article-title":"Vilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action","volume":"12","author":"Wang","year":"2015","journal-title":"Psychiatry Investig."},{"key":"10.1016\/j.ajp.2017.01.016_bib0140","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4068\/cmj.2016.52.2.91","article-title":"Vilazodone for the treatment of depression: an update","volume":"52","author":"Wang","year":"2016","journal-title":"Chonnam Med. J."},{"key":"10.1016\/j.ajp.2017.01.016_bib0145","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1345\/aph.1Q405","article-title":"Pregabalin for the treatment of generalized anxiety disorder","volume":"46","author":"Wensel","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ajp.2017.01.016_bib0150","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/da.10065","article-title":"Generalized anxiety disorder: prevalence, burden, and cost to society","volume":"16","author":"Wittchen","year":"2002","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.ajp.2017.01.016_bib0155","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/appy.12203","article-title":"Duloxetine in treating generalized anxiety disorder in adults: a meta-analysis of published randomized, double-blind, placebo-controlled trials","volume":"8","author":"Zhang","year":"2016","journal-title":"Asia Pac. Psychiatry"}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201816304415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201816304415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:28:44Z","timestamp":1761755324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201816304415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":31,"alternative-id":["S1876201816304415"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2017.01.016","relation":{},"ISSN":["1876-2018"],"issn-type":[{"value":"1876-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2017.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}